Dr. Corn on Sequencing Agents for Patients With mCRPC

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

There is an increasing number of agents that are FDA approved to treat patients with mCRPC, says Corn, adding that this is an exciting time to be a prostate cancer clinician and researcher because of the number of successful agents.

However, the amount of new agents has created sequencing and combination challenges. Therefore, an exciting area of research is the development of predictive biomarkers to individualize therapies for patients. At The University of Texas MD Anderson Cancer Center, Corn says that physicians frequent perform tumor biopsies to understand the heterogeneity of mCRPC.